Business Context and Reporting Period
Aptevo Therapeutics Inc. (APVO), a biopharmaceutical company based in Seattle, Washington, filed this Form 8-K on June 28, 2024, to report the entry into a material definitive agreement. The filing details a registered direct offering that closed on July 1, 2024.
Key Financial Metrics
- Net Proceeds: Approximately $2.3 million.
- Offering Price: $0.515 per share of Common Stock (or Pre-Funded Warrant) plus accompanying Common Warrants.
- Shares Issued: 5,339,806 shares of Common Stock or Pre-Funded Warrants.
- Warrants Issued: 10,679,612 Common Warrants (2 warrants per share).
- Transaction Costs: 7% cash fee paid to the placement agent (Roth Capital Partners, LLC) plus expense reimbursements.
- Use of Proceeds: Continued clinical development of product candidates, working capital, and general corporate purposes.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with healthcare-focused institutional investors. A significant material change involves the amendment of existing warrants issued on August 4, 2023, November 9, 2023, and April 15, 2024. The exercise prices of these Existing Warrants were reduced from $27.28, $10.252, and $1.35, respectively, to $0.515 per share to align with the new offering price. These amended warrants are exercisable upon stockholder approval.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance the clinical development of its product candidates. The Common Warrants issued in this offering have an exercise price of $0.515 per share, are exercisable upon stockholder approval, and expire five years following such approval. The Pre-Funded Warrants are immediately exercisable. The filing notes that the summaries of agreements are subject to the full terms of the exhibits attached to the report.
Investor Verification Checklist
- Verify the exact number of shares issued as Common Stock versus Pre-Funded Warrants.
- Confirm the status of the required stockholder approval for the exercise of Common Warrants and amended Existing Warrants.
- Review the specific terms of the warrant repricing and adjustment mechanisms in the attached exhibits.
- Assess the dilution impact of the 10,679,612 new warrants and the amended existing warrants on current shareholders.
- Check for any subsequent filings regarding the final closing details or changes in the use of proceeds.